CompletedNot Applicable

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

India200 participantsStarted 2019-02-18

Plain-language summary

The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants prescribed perampanel for the adjunctive treatment of partial onset seizures based on independent clinical judgment of treating physicians. Exclusion Criteria: * Participation in another study involving administration of an investigational drug or device whilst participating in this observational study. * Hypersensitivity \[allergic\] to perampanel.

What they're measuring

Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Timeframe: Up to 6 months

Trial details

NCT IDNCT03836924

SponsorEisai Pharmaceuticals India Pvt. Ltd

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-03-01

View on ClinicalTrials.gov More Partial Onset Seizures trials